MX358447B - Anticuerpos anti-psgl-1 y usos de los mismos. - Google Patents
Anticuerpos anti-psgl-1 y usos de los mismos.Info
- Publication number
- MX358447B MX358447B MX2013014814A MX2013014814A MX358447B MX 358447 B MX358447 B MX 358447B MX 2013014814 A MX2013014814 A MX 2013014814A MX 2013014814 A MX2013014814 A MX 2013014814A MX 358447 B MX358447 B MX 358447B
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- psgl
- cells
- polynucleotides
- kits
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a un anticuerpo monoclonal que se une inmunoespecíficamente a PSGL-1 de humano, una composición farmacéuticamente que comprende el anticuerpo, un equipo que comprende el anticuerpo y el uso farmacéutica de la composición.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161496249P | 2011-06-13 | 2011-06-13 | |
PCT/US2012/042068 WO2012174001A1 (en) | 2011-06-13 | 2012-06-12 | Anti-psgl-1 antibodies and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013014814A MX2013014814A (es) | 2014-07-22 |
MX358447B true MX358447B (es) | 2018-08-21 |
Family
ID=47357432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013014814A MX358447B (es) | 2011-06-13 | 2012-06-12 | Anticuerpos anti-psgl-1 y usos de los mismos. |
Country Status (20)
Country | Link |
---|---|
US (4) | US20130209449A9 (es) |
EP (2) | EP2718325A4 (es) |
JP (1) | JP6180408B2 (es) |
KR (1) | KR102103036B1 (es) |
CN (3) | CN108892726A (es) |
AU (1) | AU2012271845B2 (es) |
BR (1) | BR112013031892A2 (es) |
CA (1) | CA2838952C (es) |
CL (1) | CL2013003570A1 (es) |
CO (1) | CO6940376A2 (es) |
EC (1) | ECSP14013132A (es) |
IL (2) | IL229844B (es) |
MX (1) | MX358447B (es) |
NZ (1) | NZ619524A (es) |
RU (1) | RU2650817C2 (es) |
SG (1) | SG10201604767TA (es) |
TW (1) | TWI643872B (es) |
UA (1) | UA114712C2 (es) |
WO (1) | WO2012174001A1 (es) |
ZA (1) | ZA201400209B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7744888B2 (en) | 2001-08-03 | 2010-06-29 | Abgenomics Cooperatief U.A. | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
US20040116333A1 (en) | 2001-08-03 | 2004-06-17 | Rong-Hwa Lin | Modulators of P-selectin glycoprotein ligand 1 |
MY148646A (en) | 2004-05-10 | 2013-05-15 | Abgenomics Cooperatief Ua | Anti-psgl-1 antibodies |
KR20120085921A (ko) | 2004-05-11 | 2012-08-01 | 압제노믹스 코오페라티에프 유.에이. | T 세포 사멸 유도성 에피토프 |
CN108892726A (zh) | 2011-06-13 | 2018-11-27 | 艾比吉诺米克斯合作公司 | 抗psgl-1抗体及其用途 |
CA2953706A1 (en) * | 2014-07-08 | 2016-01-14 | Sanford-Burnham Medical Research Institute | Psgl-1 modulators and uses thereof |
IL260289B (en) | 2016-01-08 | 2022-08-01 | Bioalliance Cv | Quadrivalent anti-psgl-1 antibodies and uses thereof |
WO2017214941A1 (zh) * | 2016-06-16 | 2017-12-21 | 毛侃琅 | 一种提升SelP基因表达水平的慢病毒载体及其应用 |
CN111201038A (zh) | 2017-01-11 | 2020-05-26 | 戊瑞治疗有限公司 | Psgl-1拮抗剂及其用途 |
TWI787230B (zh) | 2017-01-20 | 2022-12-21 | 法商賽諾菲公司 | 抗TGF-β抗體及其用途 |
TWI832600B (zh) * | 2017-01-20 | 2024-02-11 | 美商健臻公司 | 骨靶向抗體 |
KR20240151866A (ko) | 2017-03-14 | 2024-10-18 | 파이브 프라임 테라퓨틱스, 인크. | 산성 pH에서 VISTA에 결합하는 항체 |
US12091462B2 (en) | 2018-07-11 | 2024-09-17 | Five Prime Therapeutics, Inc. | Antibodies binding to vista at acidic pH |
CA3106418A1 (en) | 2018-07-20 | 2020-01-23 | Pierre Fabre Medicament | Receptor for vista |
CA3141334A1 (en) * | 2019-06-04 | 2020-12-10 | Verseau Therapeutics, Inc. | Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof |
CN113667015B (zh) * | 2021-08-20 | 2022-10-11 | 北京康特泊瑞生物医药科技股份公司 | 靶向psgl-1蛋白的抗体及其用途 |
CA3238217A1 (en) * | 2021-11-17 | 2023-05-25 | Shih-Yao Lin | Methods of using anti-psgl-1 antibodies in combination with jak inhibitors to treat t-cell mediated inflammatory diseases or cancers |
WO2024057232A1 (en) * | 2022-09-13 | 2024-03-21 | Tetherex Pharmaceuticals Corporation | Antibodies, compositions, and methods of treatment |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5464778A (en) | 1989-03-08 | 1995-11-07 | Board Of Regents Of The University Of Oklahoma | Glycoprotein ligand for P-selectin and methods of use thereof |
US5378464A (en) | 1989-03-08 | 1995-01-03 | Board Of Regents Of The University Of Oklahoma | Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140 |
US5690933A (en) | 1989-05-31 | 1997-11-25 | Glaxo Wellcome Inc. | Monoclonal antibodies for inducing tolerance |
US5709859A (en) | 1991-01-24 | 1998-01-20 | Bristol-Myers Squibb Company | Mixed specificity fusion proteins |
US6309639B1 (en) | 1991-02-05 | 2001-10-30 | The Board Of Regents Of The University Of Oklahoma | Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand |
US6124267A (en) | 1991-02-05 | 2000-09-26 | Southpac Trust Internationals, Inc. | O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1 |
US5972625A (en) | 1991-05-06 | 1999-10-26 | The Regents Of The University Of California | Assays for inhibitors of leukocyte adhesion |
ATE179210T1 (de) | 1992-03-17 | 1999-05-15 | Novartis Erfind Verwalt Gmbh | Gentechnologisch hergestellte antikörper |
US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
US5843707A (en) | 1992-10-23 | 1998-12-01 | Genetics Institute, Inc. | Nucleic acid encoding a novel P-selectin ligand protein |
US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
US5710123A (en) | 1992-12-18 | 1998-01-20 | Centocor, Inc. | Peptide inhibitors of selectin binding |
AU694933B2 (en) | 1993-01-25 | 1998-08-06 | Dana-Farber Cancer Institute, Inc. | Chimeric L- and P-selectin by exchange of domains - uses thereof |
WO1995014787A1 (en) | 1993-11-22 | 1995-06-01 | Centocor, Inc. | Peptide inhibitors of selecting binding |
FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
KR100523506B1 (en) | 1995-08-03 | 2005-10-24 | Peptide and O-glycan inhibitors of selectin mediated inflammation | |
US6348581B1 (en) | 1996-10-31 | 2002-02-19 | The Dow Chemical Company | High affinity humanized anti-TAG-72 monoclonalantibodies |
WO1999043353A2 (en) | 1998-02-26 | 1999-09-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | Combination anti-selectin and immunosuppressant therapy |
ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
IL142717A0 (en) | 1998-10-30 | 2002-03-10 | Genetics Inst | Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists |
EP2270147B2 (en) | 1999-04-09 | 2020-07-22 | Kyowa Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US6696620B2 (en) | 2000-05-02 | 2004-02-24 | Epicyte Pharmaceutical, Inc. | Immunoglobulin binding protein arrays in eukaryotic cells |
AU2001261735B2 (en) | 2000-05-19 | 2006-09-21 | The Center For Blood Research, Inc. | Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity |
EP1325123A4 (en) | 2000-09-12 | 2004-07-21 | Inst Genetics Llc | STENOSE- OR RESEARCH INHIBITION BY P-SELECTIN ANTAGONISTS |
CZ20031982A3 (cs) | 2000-12-29 | 2004-09-15 | Bio-Technology General Corp. | Izolované molekuly zahrnující epitopy obsahující sulfatované sloučeniny, protilátky proti takovým epitopům a jejich použití |
US20040001839A1 (en) | 2000-12-29 | 2004-01-01 | Avigdor Levanon | Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
US20040002450A1 (en) | 2000-12-29 | 2004-01-01 | Janette Lazarovits | Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
CA2385745C (en) | 2001-06-08 | 2015-02-17 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
US6884619B2 (en) | 2001-07-17 | 2005-04-26 | Yale University | Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors |
US7744888B2 (en) | 2001-08-03 | 2010-06-29 | Abgenomics Cooperatief U.A. | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
US20040116333A1 (en) | 2001-08-03 | 2004-06-17 | Rong-Hwa Lin | Modulators of P-selectin glycoprotein ligand 1 |
PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
BR0312483A (pt) | 2002-07-01 | 2005-08-09 | Savient Pharmaceuticals Inc | Anticorpos e seus usos |
US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
JP2007527393A (ja) | 2003-06-30 | 2007-09-27 | バイオ−テクノロジー・ジェネラル(イスラエル)リミテッド | 特異的ヒト抗体 |
PT1707627E (pt) * | 2003-12-25 | 2013-01-24 | Kyowa Hakko Kirin Co Ltd | Mutante antagonista de anticorpo anti-cd40 |
EP1720996A4 (en) * | 2004-02-13 | 2007-03-21 | Immunomedics Inc | RECOMBINANT CYTOTOXIC RASES CONTAINING FUSION PROTEINS |
KR100891620B1 (ko) | 2004-04-13 | 2009-04-02 | 에프. 호프만-라 로슈 아게 | 항-p-셀렉틴 항체 |
MY148646A (en) * | 2004-05-10 | 2013-05-15 | Abgenomics Cooperatief Ua | Anti-psgl-1 antibodies |
KR20120085921A (ko) | 2004-05-11 | 2012-08-01 | 압제노믹스 코오페라티에프 유.에이. | T 세포 사멸 유도성 에피토프 |
US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
TWI309240B (en) * | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
TWI461436B (zh) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類cd134(ox40)之人類單株抗體及其製造及使用方法 |
AU2007275467B2 (en) * | 2006-07-14 | 2013-12-05 | Ac Immune S.A. | Humanized antibody against amyloid beta |
MX2009010092A (es) * | 2007-03-22 | 2010-02-09 | Genentech Inc | Anticuerpos anti ige apoptoticos. |
AU2008234248C1 (en) * | 2007-03-29 | 2015-01-22 | Genmab A/S | Bispecific antibodies and methods for production thereof |
EP2666787B1 (en) * | 2007-05-31 | 2022-02-09 | Genmab A/S | STABLE IgG4 ANTIBODIES |
BRPI0812400A2 (pt) | 2007-06-05 | 2014-10-29 | Univ Yale | Unidade, hibridoma, composição farmacêutica, método para identificar uma unidade, anticorpo isolado a uma unidade de ligação de antígeno do mesmo, molécula peptídica, e, uso da unidade. |
CA2697612A1 (en) * | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Anti-igf-1r antibodies and uses thereof |
JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
US8092804B2 (en) * | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
WO2009103791A1 (en) * | 2008-02-22 | 2009-08-27 | Genmab A/S | Methods for assissing the risk of adverse events upon treatment with igg4 antibodies |
WO2009140623A2 (en) * | 2008-05-15 | 2009-11-19 | Selexys Pharmaceuticals Corporation | Anti-psgl-1 antibodies and methods of identification and use |
AU2010223569A1 (en) * | 2009-03-12 | 2011-11-03 | Imed Ab | Human antibodies against human Fas and their use |
AR077594A1 (es) * | 2009-07-31 | 2011-09-07 | Organon Nv | Anticuerpos completamente humanos para btla (atenuante de linfocitos b y t) |
CN108892726A (zh) | 2011-06-13 | 2018-11-27 | 艾比吉诺米克斯合作公司 | 抗psgl-1抗体及其用途 |
KR20170063507A (ko) | 2014-06-20 | 2017-06-08 | 어브게노믹스 인터내셔널 인코포레이티드 | Her2 항체-약물 접합체 |
-
2012
- 2012-06-12 CN CN201810722769.2A patent/CN108892726A/zh active Pending
- 2012-06-12 SG SG10201604767TA patent/SG10201604767TA/en unknown
- 2012-06-12 CN CN202211394154.4A patent/CN116063522A/zh active Pending
- 2012-06-12 EP EP12799966.2A patent/EP2718325A4/en not_active Ceased
- 2012-06-12 NZ NZ619524A patent/NZ619524A/en unknown
- 2012-06-12 AU AU2012271845A patent/AU2012271845B2/en active Active
- 2012-06-12 KR KR1020147000603A patent/KR102103036B1/ko active IP Right Grant
- 2012-06-12 EP EP21168455.0A patent/EP3925978A1/en active Pending
- 2012-06-12 JP JP2014515918A patent/JP6180408B2/ja active Active
- 2012-06-12 US US13/494,398 patent/US20130209449A9/en not_active Abandoned
- 2012-06-12 RU RU2013158083A patent/RU2650817C2/ru active
- 2012-06-12 WO PCT/US2012/042068 patent/WO2012174001A1/en active Application Filing
- 2012-06-12 UA UAA201314798A patent/UA114712C2/uk unknown
- 2012-06-12 CA CA2838952A patent/CA2838952C/en active Active
- 2012-06-12 MX MX2013014814A patent/MX358447B/es active IP Right Grant
- 2012-06-12 BR BR112013031892A patent/BR112013031892A2/pt not_active Application Discontinuation
- 2012-06-12 CN CN201280039482.0A patent/CN103732626A/zh active Pending
- 2012-06-13 TW TW101121146A patent/TWI643872B/zh active
-
2013
- 2013-04-17 US US13/865,085 patent/US20130251708A1/en not_active Abandoned
- 2013-12-08 IL IL229844A patent/IL229844B/en unknown
- 2013-12-12 CL CL2013003570A patent/CL2013003570A1/es unknown
-
2014
- 2014-01-09 ZA ZA2014/00209A patent/ZA201400209B/en unknown
- 2014-01-13 EC ECSP14013132 patent/ECSP14013132A/es unknown
- 2014-01-13 CO CO14004726A patent/CO6940376A2/es unknown
-
2021
- 2021-08-30 US US17/460,883 patent/US11897964B2/en active Active
- 2021-10-14 IL IL287270A patent/IL287270A/en unknown
-
2023
- 2023-12-26 US US18/396,607 patent/US20240124604A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX358447B (es) | Anticuerpos anti-psgl-1 y usos de los mismos. | |
MY171038A (en) | Bispecific antigen binding molecules | |
MY169358A (en) | Bispecific t cell activating antigen binding molecules | |
MX2020009692A (es) | Moleculas biespecificas de union a antigeno activadoras de celulas t. | |
MX2015010843A (es) | Moleculas biespecificas de union al antigeno que activan celulas t. | |
PH12016502505A1 (en) | Bispecific t cell activating antigen binding molecules | |
MX2015010350A (es) | Moleculas de union a antigeno biespecificas que activan la celula t. | |
MY184889A (en) | T cell activating bispecific antigen binding molecules | |
MX2018003631A (es) | Moleculas biespecificas de union a antigeno activadoras de celulas t. | |
MX366965B (es) | Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina. | |
PH12014501108A1 (en) | Anti-il-36r antibodies | |
EA201490636A1 (ru) | Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований | |
SG194465A1 (en) | Novel immunoconjugates | |
MX2016002571A (es) | Regulador de ph de transduccion. | |
UA116766C2 (uk) | Зв'язувальна молекула, яка є біоспецифічною до вcma і cd3 | |
MX359854B (es) | Anticuerpos anti-cxcr3. | |
MX349662B (es) | Anticuerpos de antigenos antitumorales y metodos de uso. | |
MX360620B (es) | Anticuerpos anti kit y usos de los mismos. | |
MX2014002996A (es) | Anticuerpos anti - egfr/anti - igf-1r bisespecificos. | |
MX2014013676A (es) | Uso de moleculas de enlace a la semaforina-4d para promover la neurogenesis despues de la apoplejia. | |
TN2013000265A1 (en) | Anti-cd38 antibodies | |
TN2014000207A1 (en) | Anti il-36r antibodies | |
TH157671A (th) | แอนติ-psgl-1 แอนติบอดีและการใช้ของมัน |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |